7057 POSTER A Phase 1 Single Dose Open-label Reduced/staged Pharmacokinetic (PK) and Safety Study of Abiraterone Acetate (AA) in Men With Impaired Renal Function von Marbury, T, Stonerock, R, Tran, N, Gonzalez, M, Jiao, J, Breeding, J, Haqq, C.M, Molina, A, Acharya, M

Volltext

7056 POSTER QT/QTc Studies of Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Analysis of 3 Phase 1/2 Studies von Ryan, C.J, Danila, D.C, Tolcher, A, Chi, K.N, Tran, N, Knoblauch, R, Kheoh, T, Haqq, C.M, Scher, H.I, Molina, A

Volltext

7015 POSTER DISCUSSION Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From... von Sternberg, C.N, Scher, H.I, Molina, A, North, S, Mainwaring, P, Hao, Y, Gagnon, D, Kheoh, T, Haqq, C.M, de Bono, J

Volltext

7001 ORAL Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase... von Harland, S, de Bono, J.S, Haqq, C.M, Staffurth, J.N, Hao, Y, Gagnon, D, Liu, C, Sternberg, C.N, Molina, A, Scher, H.I

Volltext

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cance... von Fizazi, K, Scher, H.I, Molina, A, Logothetis, C.J, Jones, R.J, Staffurth, J.N, Li, J, Kheoh, T, Haqq, C.M, de Bono, J.S

Volltext

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy von Sternberg, C.N., Molina, A., North, S., Mainwaring, P., Fizazi, K., Hao, Y., Rothman, M., Gagnon, D.D., Kheoh, T., Haqq, C.M., Cleeland, C., de Bono, J.S., Scher, H.I.

Volltext

Androgen dynamics and serum PSA in patients treated with abiraterone acetate von Ryan, C J, Peng, W, Kheoh, T, Welkowsky, E, Haqq, C M, Chandler, D W, Scher, H I, Molina, A

Volltext

127 Improved survival in elderly (≥75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progress... von Mulders, P.F.A, Molina, A, Marberger, M, Saad, F, Li, J.H, Kheoh, T, Haqq, C.M, Fizazi, K

Volltext